The aim of the project is to develop a new cancer treatment in the form of antibodies to SLAMF6 that can activate the body’s own T cells to attack cancer stem cells, primarily in acute myeloid leukaemia (AML) but potentially also in other cancers. The funds sought would enable the development of therapeutic antibodies by financing patent protection for SLAMF6 as a target for leukaemia stem cells and for the promising antibody to SLAMF6 that we have recently generated.
Menu